Search

In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.

MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.

Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

Learn how to keep your immune system balanced.

Learn how MSK doctors are exploring the use of less radiation in neuroblastoma treatment so children can avoid side effects.

Learn about the 21st Century Cures Act, which set out to improve the way providers share information to coordinate the care of their patients and to improve patients’ access to their own medical information.